Prognosis and Management of Polymyalgia Rheumatica

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 1981 Feb 1

PMID 7469518

Citations 58

Authors

J G Jones

B L Hazleman

Affiliations

Soon will be listed here.

Abstract

Polymyalgia rheumatica (PMR) is considered to be a benign disease by some, while others think it is a more serious illness which required similar treatment to giant cell arteritis (GCA). The progress of 85 patients with PMR who presented to a district general hospital has been studied in an attempt to study this relationship. Thirty-eight patients had PMR alone, and 14 developed PMR and GCA within 1 month. Five patients presented with GCA and then developed PMR, and 28 patients developed symptoms of GCA after presenting with PMR (PMR leads to GCA). Arteritis and complications developed up to 9 years after the onset of PMR (mean 1 year). Twenty-two patients (26%) developed some cerebral or visual complication. Fifteen of these patients were in the PMR leads to GCA group. All 6 patients with permanent loss of vision were in this group. Seven patients developed complications while on corticosteroids. 97% of patients required corticosteroids for at least 1 year; 32% of patients still required 10 mg of prednisone or more after 1 year. PMR is not a benign disease.

Citing Articles

The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients.

Nielsen A, Hansen I, Nielsen B, Kjaer S, Blegvad-Nissen J, Rewers K Eur J Nucl Med Mol Imaging. 2024; 51(9):2614-2624.

PMID: 38563881 PMC: 11224098. DOI: 10.1007/s00259-024-06697-8.

Polymyalgia rheumatica: An update (Review).

Florescu M, Bobirca F, Florescu A, Padureanu V, Bobirca A, Ciurea P Exp Ther Med. 2023; 26(6):543.

PMID: 37928511 PMC: 10623218. DOI: 10.3892/etm.2023.12242.

Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica.

Perricone C, Cafaro G, Fiumicelli E, Bursi R, Bogdanos D, Riccucci I Clin Exp Med. 2022; 23(7):3391-3397.

PMID: 36566303 DOI: 10.1007/s10238-022-00976-0.

The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.

Manzo C, Hysa E, Castagna A, Isetta M J Pers Med. 2022; 12(3).

PMID: 35330329 PMC: 8953282. DOI: 10.3390/jpm12030329.

Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.

Toro-Gutierrez C, Canas C, Mantilla R, Beltran S, Pastrana-Gonzalez V, Vecino M J Transl Autoimmun. 2021; 4:100115.

PMID: 34485886 PMC: 8391016. DOI: 10.1016/j.jtauto.2021.100115.

References

Huston K, Hunder G, Lie J, Kennedy R, ELVEBACK L . Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978; 88(2):162-7. DOI: 10.7326/0003-4819-88-2-162. View

Ettlinger R, Hunder G, WARD L . Polymyalgia rheumatica and giant cell arteritis. Annu Rev Med. 1978; 29:15-22. DOI: 10.1146/annurev.me.29.020178.000311. View

Hunder G, Allen G . Giant cell arteritis: a review. Bull Rheum Dis. 1978; 29(3-4):980-6. View

Malmvall B, Bengtsson B . Giant cell arteritis. Clinical features and involvement of different organs. Scand J Rheumatol. 1978; 7(3):154-8. DOI: 10.3109/03009747809095645. View

COOMES E, Ellis R, Kay A . A prospective study of 102 patients with the polymyalgia rheumatica syndrome. Rheumatol Rehabil. 1976; 15(4):270-9. DOI: 10.1093/rheumatology/15.4.270. View

HOLLENHORST R, Brown J, WAGENER H, SHICK R . Neurologic aspects of temporal arteritis. Neurology. 1960; 10:490-8. DOI: 10.1212/wnl.10.5.490. View

Healey L, WILSKE K . Manifestations of giant cell arteritis. Med Clin North Am. 1977; 61(2):261-70. DOI: 10.1016/s0025-7125(16)31331-1. View

Hamilton Jr C, SHELLEY W, Tumulty P . Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica. Medicine (Baltimore). 1971; 50(1):1-27. View

Fauchald P, RYGVOLD O, OYSTESE B . Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med. 1972; 77(6):845-52. DOI: 10.7326/0003-4819-77-6-845. View

10.

Myles A . Polymyalgia rheumatica and giant cell arteritis: a seven-year survey. Rheumatol Rehabil. 1975; 14(4):231-5. DOI: 10.1093/rheumatology/14.4.231. View

11.

Klein R, Campbell R, Hunder G, Carney J . Skip lesions in temporal arteritis. Mayo Clin Proc. 1976; 51(8):504-10. View

12.

Olhagen B . POLYMYALGIA RHEUMATICA. A FORM OF SENILE ARTERITIS?. Acta Rheumatol Scand. 1963; 9:157-64. View

13.

Rynes R, Mika P, Bartholomew L . Development of giant cell (temporal) arteritis in a patient 'adequately' treated for polymyalgia rheumatica. Ann Rheum Dis. 1977; 36(1):88-90. PMC: 1006638. DOI: 10.1136/ard.36.1.88. View

14.

Harrison M, Bevan A . Early symptoms of temporal arteritis. Lancet. 1967; 2(7517):638-40. DOI: 10.1016/s0140-6736(67)90684-8. View